sCD30 and sCD40L detection in patients with Osteosarcoma, chondrosarcoma and Ewing sarcoma

Iranian Journal of Immunology

Volumn 10, Issue 4, 2013, Pages 229-237

  Solooki, Saeed ^a   Khozaei, Arash ^a   Shamsdin, Seyedeh Azra ^b   Emami, Mohammad Jafar ^a   Khademolhosseini, Farnaz ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone; Cancer; Sarcoma; sCD30; sCD40L

Indexed keywords

CD30 ANTIGEN; CD40 LIGAND; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CHONDROSARCOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; ADOLESCENT; BLOOD; BONE NEOPLASMS; CHILD; IMMUNOLOGY; PROGNOSIS; SARCOMA, EWING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD30; BONE NEOPLASMS; CD40 LIGAND; CHILD; CHONDROSARCOMA; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PROGNOSIS; SARCOMA, EWING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84930067016     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Williams, Wilkins. Musculoskeletal disorders Bone, Wolters, Professional Guide to Diseases, 9th ed, Philadelphia: Springhouse, Kluwer Health/Lippincott; 2009:864-8
2. Robert K. Heck JR. Malignant tumors of bone, Osteosarcoma, Canal ST, Campbell's operative orthopedics, 11th ed, New York: Mosby; 2008. p. 901-7
3. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the IstitutoOrtopedico Rizzoli according to the IOR/OS2 protocol: an update report. J Clin Oncol.2000; 18:4016-27
4. Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. ActaRadiol Oncol.1984; 23:159-62
5. Sanerkin, N. The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach. Cancer.1980; 45:582-94
6. Robert K. Heck JR. Malignant tumors of bone, Osteosarcoma, Canal ST, Campbell's operative orthopedics, 11th ed, New York: Mosby; 2008. p. 907-10
7. Josimovic-Alasevic O, Durkop H, Schwarting R, Backé E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme linked immunosorbent assay. Eur J Immunol. 1989; 19:157-62
8. Lollini PL, Landuzzi L, Frabetti F, Rossi I, Nicoletti G, Scotlandi K, et al. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res.1998; 4:1843-9
9. Ciferská H, Horák P, Hermanová Z, Ordeltová M, Zadrazil J, Tichý T, et al.The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value.Clin Rheumatol.2007; 26:723-8
10. Kim LH, Eow GI, Peh SC, Poppema S. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.Pathology. 2003; 35:428-35
11. Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009; 114:2730-2
12. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloidderived suppressor cells in cancer. Cancer Res. 2010; 70:99-108
13. Hansen HP, Kisselva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer.1995; 63:750-6
14. Froese P, Lemke H, Gerdes J, Havsteen, B, Schwarting R, Hansen H. Biochemical characterization and biosynthesis of the Ki-l antigen in Hodgkin-derived and virus transformed human B and T lymphoid cell lines. J Immunol.1987; 139:2081-7
15. Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H.BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989; 74:1678-89
16. Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule:a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995; 85:1-14
17. Baccia G, Fornia C, Longhia A, Ferraria S, Donatib D, De Paolisa M, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvantchemotherapies.402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer. 2004; 40:73-83
18. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.Cell.1992; 68:421-7
19. Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R. Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumors. Wien Med Wochenschr. 2003; 153:40-2
20. Pfreundschuh M, Pohl C, Berenbeck C, Schroeder J, Jung W, Schmits R, et al. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer.1990; 45:869-74
21. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, et al.Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol. 1998; 103:270-5
22. Van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S A, et al.CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996; 149:1953-61